Global In Silico Clinical Trials Market: Regional Insights
Based on geography, the global in silico clinical trials market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing prevalence of chronic, infectious, and neurological diseases, rise in number of clinical trials, and rise in drug discovery and development in the region. For instance, with the rise in burden of chronic, infectious, and neurological diseases, the demand for safe and effective drugs and medical device is also increasing. According to the Centers for Disease Control and Prevention (CDC), chronic diseases, such as heart disease, cancer, and diabetes, are the leading causes of death and disability in the United States.
Europe and Asia Pacific are also expected to witness robust growth in the global in silico clinical trials market due to the rise in burden of chronic, infectious, and neurological diseases, rise in drug discovery and development, and increase in number of clinical trials in these regions. For instance, according to the European Medicines Agency - European Union, in the EU / EEA, more than 4,000 clinical trials are authorised each year, of which 60% of clinical trials are sponsored by the pharma industry and 40% by non-commercial sponsors. As per the Clinical Trials Registry India (CTRI), India approved over 100 global clinical trials in 2021, the highest since 2013.
In Silico Clinical Trials Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients